Publications by authors named "Eva Hellstroem Lindberg"
Lancet Haematol
February 2021
Article Synopsis
- The study investigates the effectiveness of hypomethylating agents in treating patients with chronic myelomonocytic leukaemia (CMML) by comparing their outcomes to those receiving other treatments, like hydroxyurea and intensive chemotherapy.
- Data was collected retrospectively from 949 patients across 38 centers in the USA and Europe between late 2017 and early 2019, focusing on overall survival and treatment progression.
- Findings showed that patients first treated with hypomethylating agents had a median overall survival of 20.7 months, which was better compared to 15.6 months for those treated with hydroxyurea, indicating potential benefits of hypomethylating agents in this patient group.
